DE69904922D1 - Pharmazeutische zusammensetzung zur behandlung von alkoholabhängigkeit, die opioid antagonisten mit nmda-rezeptorkomplex-modulatoren enthält - Google Patents

Pharmazeutische zusammensetzung zur behandlung von alkoholabhängigkeit, die opioid antagonisten mit nmda-rezeptorkomplex-modulatoren enthält

Info

Publication number
DE69904922D1
DE69904922D1 DE69904922T DE69904922T DE69904922D1 DE 69904922 D1 DE69904922 D1 DE 69904922D1 DE 69904922 T DE69904922 T DE 69904922T DE 69904922 T DE69904922 T DE 69904922T DE 69904922 D1 DE69904922 D1 DE 69904922D1
Authority
DE
Germany
Prior art keywords
nmda receptor
receptor complex
treatment
pharmaceutical composition
opioid antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69904922T
Other languages
English (en)
Other versions
DE69904922T2 (de
Inventor
Martine Daoust
Yves Le Buclay Bonhomme
Philippe Durbin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sante SAS
Original Assignee
LIPHA SAS
LIPHA Liyonnaise Industrielle Pharmaceutique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LIPHA SAS, LIPHA Liyonnaise Industrielle Pharmaceutique filed Critical LIPHA SAS
Application granted granted Critical
Publication of DE69904922D1 publication Critical patent/DE69904922D1/de
Publication of DE69904922T2 publication Critical patent/DE69904922T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69904922T 1998-03-26 1999-03-26 Pharmazeutische zusammensetzung zur behandlung von alkoholabhängigkeit, die opioid antagonisten mit nmda-rezeptorkomplex-modulatoren enthält Expired - Lifetime DE69904922T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98400723A EP0945133A1 (de) 1998-03-26 1998-03-26 Pharmazeutische Zusammensetzung zur Behandlung von Alkohol- oder Drogenabhängigkeit, die Opioid Antagonisten mit NMDA-Rezeptorkomplex-Modulatoren enthält
EP98400723 1998-03-26
PCT/EP1999/002337 WO1999048500A1 (en) 1998-03-26 1999-03-26 Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a nmda receptor complex modulator

Publications (2)

Publication Number Publication Date
DE69904922D1 true DE69904922D1 (de) 2003-02-20
DE69904922T2 DE69904922T2 (de) 2004-01-08

Family

ID=8235311

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69904922T Expired - Lifetime DE69904922T2 (de) 1998-03-26 1999-03-26 Pharmazeutische zusammensetzung zur behandlung von alkoholabhängigkeit, die opioid antagonisten mit nmda-rezeptorkomplex-modulatoren enthält

Country Status (18)

Country Link
US (1) US6512009B1 (de)
EP (2) EP0945133A1 (de)
KR (1) KR20010034678A (de)
AT (1) ATE230993T1 (de)
AU (1) AU758569B2 (de)
BR (1) BR9909138A (de)
CA (1) CA2325739C (de)
CZ (1) CZ296367B6 (de)
DE (1) DE69904922T2 (de)
DK (1) DK1063995T3 (de)
ES (1) ES2190205T3 (de)
HK (1) HK1032542A1 (de)
HU (1) HU226555B1 (de)
NO (1) NO319313B1 (de)
PL (1) PL193241B1 (de)
RU (1) RU2226107C2 (de)
SK (1) SK284623B6 (de)
WO (1) WO1999048500A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2389627T3 (es) * 1998-07-20 2012-10-29 Virbac (Australia) Pty Ltd Formulación para bioimplantes
US8052982B2 (en) 1998-07-20 2011-11-08 Peptech Animal Health Pty Limited Bioimplant formulation comprising lecithin and stearin
WO2001052851A1 (en) * 2000-01-22 2001-07-26 Albert Shulman Methods for the treatment of substance abuse
EP1262196A3 (de) * 2001-05-23 2002-12-18 Pfizer Products Inc. Kombination eines Inhibitoren der Monoaminwiederaufnahme und eines Opioidanatagonisten zur Verwendung in Alkoholismus und Alkoholsucht
DE10129265A1 (de) * 2001-06-18 2003-01-02 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie
ES2187288B1 (es) 2001-09-24 2004-09-16 Garbil Pharma Investigacion Chile Ltda Aminas como agentes anti-alcoholismo.
PT2561860T (pt) 2002-05-31 2018-05-08 Titan Pharmaceuticals Inc Dispositivo polimérico implantável para a libertação prolongada de buprenorfina
EP2959893A1 (de) 2002-12-13 2015-12-30 DURECT Corporation Orales arzneimittelverabreichungssystem mit hochviskosen flüssigkeitsträgermaterialien
US20040224020A1 (en) * 2002-12-18 2004-11-11 Schoenhard Grant L. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
EP1610791B1 (de) * 2003-03-31 2011-02-23 Titan Pharmaceuticals, Inc. Polymeres implantat zur verzögerten freisetzung von dopamin antagonisten
MXPA05012768A (es) * 2003-05-30 2006-02-22 Titan Pharmaceuticals Inc Dispositivo polimerico implantable para liberacion prolongada de nalmefeno.
US20070099947A1 (en) * 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
MX2009006672A (es) * 2006-12-19 2009-10-26 Univ Virginia Efectos combinados de topiramato y ondansetron sobre el consumo de alcohol.
WO2009088414A2 (en) 2007-12-06 2009-07-16 Durect Corporation Oral pharmaceutical dosage forms
DK2255184T3 (da) 2008-02-28 2013-07-22 Univ Virginia Patent Found Serotonintransportergen og behandling af alkoholisme
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
AU2011274355B2 (en) 2010-07-02 2016-10-27 University Of Virginia Patent Foundation Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
CA2848211A1 (en) 2011-09-09 2013-03-14 University Of Virginia Patent Foundation Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
RU2476209C1 (ru) * 2012-02-29 2013-02-27 Станислав Анатольевич Кедик Имплантируемое лекарственное средство на основе налтрексона для лечения пациентов, зависимых от алкоголя или опиатов
CA2905131A1 (en) 2013-03-15 2014-09-18 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
GB201308440D0 (en) * 2013-05-10 2013-06-19 Dalgleish Angus Therapeutic
WO2023023038A1 (en) * 2021-08-17 2023-02-23 Yale University Treatment compositions and methods

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0828489A4 (de) * 1996-03-13 2001-04-04 Univ Yale Raucherentwöhnungsbehandlung unter verwendung von naltrexon und verwandten verbindungen

Also Published As

Publication number Publication date
CZ296367B6 (cs) 2006-02-15
NO20004788L (no) 2000-11-24
NO319313B1 (no) 2005-07-11
HUP0101546A3 (en) 2002-10-28
KR20010034678A (ko) 2001-04-25
AU3522699A (en) 1999-10-18
EP1063995A1 (de) 2001-01-03
HUP0101546A2 (hu) 2001-09-28
NO20004788D0 (no) 2000-09-25
PL343069A1 (en) 2001-07-30
US6512009B1 (en) 2003-01-28
CZ20003525A3 (cs) 2001-04-11
PL193241B1 (pl) 2007-01-31
DE69904922T2 (de) 2004-01-08
AU758569B2 (en) 2003-03-27
HU226555B1 (en) 2009-03-30
EP1063995B1 (de) 2003-01-15
SK284623B6 (sk) 2005-08-04
ES2190205T3 (es) 2003-07-16
DK1063995T3 (da) 2003-03-10
CA2325739C (en) 2007-05-15
EP0945133A1 (de) 1999-09-29
BR9909138A (pt) 2000-12-05
CA2325739A1 (en) 1999-09-30
RU2226107C2 (ru) 2004-03-27
SK14282000A3 (sk) 2001-05-10
WO1999048500A1 (en) 1999-09-30
ATE230993T1 (de) 2003-02-15
HK1032542A1 (en) 2001-07-27

Similar Documents

Publication Publication Date Title
DE69904922D1 (de) Pharmazeutische zusammensetzung zur behandlung von alkoholabhängigkeit, die opioid antagonisten mit nmda-rezeptorkomplex-modulatoren enthält
FI960727A (fi) Neurokiniiniantagonisteina käyttökelpoiset heterosyklit
ATE175114T1 (de) Pharmazeutische zusammensetzungen enthaltend einen opiat antagonist und calcium salze, ihre verwendung zur behandlung von endorphin- vermittelten krankheiten
ES2181055T3 (es) Formulaciones galenicas que contienen antagonistas de opiaceos.
ATE256463T1 (de) Pharmazeutische zubereitung zur verwendung in der behandlung von diabetes
DE69017302D1 (de) Zentrale Cholecystokinin-Antagonisten zur Behandlung von psychiatrischen Krankheiten.
AR002459A1 (es) Antagonistas de vasopresina de benzacepina triciclicos, una composicion farmaceutica que los contiene, un metodo para tratar enfermedades y unprocedimiento para su preparacion.
DE59609508D1 (de) Konjugat enthaltend dtpa und albumin zur individuellen dosierung von arzneimitteln
PT101444A (pt) Associacao sinergizante com efeito antagonista dos receptores nk1 e nk2, uso de produtos com actividade antagonista dos receptores nk1 e nk2 na sua preparacao e composicao farmaceutica contendo a referida associacao
EE200100520A (et) N-(2-fenüül-4-aminobutüül)-1-naftamiidid neurokiniin-1-retseptori antagonistidena
DE60134735D1 (de) Neue neurokinin-antagonisten zum gebrauch als arzneimittel
DE59914183D1 (de) Abgabeeinrichtung für eine zusammensetzung einer pharmazeutisch wirksamen substanz
DE60114597D1 (de) Naphthamid-neurokinin antagonisten zur verwendung als medikamente
BR0211323A (pt) Combinação de ingredientes ativos, uso de uma combinação de ingredientes ativos e método de terapia farmacológica de dependência de nicotina
EA200401617A1 (ru) Комбинация nmda-антагониста и ингибиторов ацетилхолинэстеразы для лечения болезни альцгеймера
BR0311881A (pt) Combinações de inbidores de pde-v e antagonistas de nk1 para o tratamento de depressão
ATE402178T1 (de) Substituierte 5,6,6a,11b-tetrahydro-7-oxa-5-aza- benzoäcüfluoren-6-carbonsäurederivate als nmda- antagonisten
RS49796B (sr) UPOTREBA SOLI 3α, 7α-DIHIDROKSI-12-KETO-5β-HOLANSKE KISELINE KAO AKTIVNE SUPSTANCE ZA IZRADU LEKOVA ZA LEČENJE DIJABETESA

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: MERCK SANTE, LYON, FR

8364 No opposition during term of opposition